We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+25.75%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.5B
AUM Growth
+$474M
Cap. Flow
+$174M
Cap. Flow %
4.97%
Top 10 Hldgs %
60.94%
Holding
54
New
11
Increased
8
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$94.1M
2
IRON icon
Disc Medicine
IRON
+$93.1M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$85.6M
4
VOR icon
Vor Biopharma
VOR
+$80M
5
IMVT icon
Immunovant
IMVT
+$72.4M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$87.5M
2
ABVX
Abivax
ABVX
+$74.6M
3
EYPT icon
EyePoint Inc
EYPT
+$65.3M
4
GPCR icon
Structure Therapeutics
GPCR
+$53.4M
5
LQDA icon
Liquidia Corp
LQDA
+$48.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$9.89B
$722M 20.65%
6,481,085
-630,511
-9% -$74.6M
CGON icon
2
CG Oncology
CGON
$6.59B
$248M 7.11%
3,670,206
– –
TNGX icon
3
Tango Therapeutics
TNGX
$3.94B
$220M 6.3%
10,531,071
-2,231,023
-17% -$31.1M
COGT icon
4
Cogent Biosciences
COGT
$6.02B
$190M 5.45%
4,946,894
-921,268
-16% -$34M
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$170M 4.87%
4,286,480
– –
DNTH icon
6
Dianthus Therapeutics
DNTH
$5.92B
$141M 4.03%
1,676,624
– –
TYRA icon
7
Tyra Biosciences
TYRA
$1.49B
$124M 3.56%
3,248,980
+350,877
+12% +$11.4M
IMVT icon
8
Immunovant
IMVT
$8.51B
$111M 3.17%
4,457,988
+2,797,055
+168% +$72.4M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.51B
$105M 3%
+11,020,968
New +$85.6M
MIRM icon
10
Mirum Pharmaceuticals
MIRM
$5.94B
$98.1M 2.81%
1,062,049
+1,000,000
+1,612% +$94.1M
VOR icon
11
Vor Biopharma
VOR
$1.34B
$96.5M 2.76%
+5,673,078
New +$80M
SYRE icon
12
Spyre Therapeutics
SYRE
$7.97B
$95.9M 2.74%
1,900,582
– –
AMLX icon
13
Amylyx Pharmaceuticals
AMLX
$3.87B
$86.8M 2.48%
6,243,812
– –
IRON icon
14
Disc Medicine
IRON
$3.07B
$85.8M 2.45%
+1,341,862
New +$93.1M
DYN icon
15
Dyne Therapeutics
DYN
$4.68B
$83.7M 2.39%
4,615,144
– –
GLUE icon
16
Monte Rosa Therapeutics
GLUE
$1.14B
$76M 2.18%
4,622,151
– –
SVRA icon
17
Savara
SVRA
$1.08B
$67.5M 1.93%
12,362,205
– –
RVMD icon
18
Revolution Medicines
RVMD
$44.6B
$56.1M 1.6%
576,473
+140,000
+32% +$14.1M
KOD icon
19
Kodiak Sciences
KOD
$2.37B
$55.1M 1.58%
1,445,538
– –
LBRX
20
LB Pharmaceuticals
LBRX
$1.54B
$45.3M 1.3%
1,839,489
+94,474
+5% +$2.18M
SRZN icon
21
Surrozen
SRZN
$264M
$42.9M 1.23%
+1,473,101
New +$35.3M
ADCT icon
22
ADC Therapeutics
ADCT
$146M
$42.7M 1.22%
11,390,175
– –
RLAY icon
23
Relay Therapeutics
RLAY
$4.11B
$42.5M 1.22%
4,273,356
+1,053,170
+33% +$9.42M
FULC icon
24
Fulcrum Therapeutics
FULC
$294M
$40.3M 1.15%
5,250,000
– –
BHVN icon
25
Biohaven
BHVN
$2.33B
$39.2M 1.12%
4,631,317
– –
1
2 3

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q1 2026 Portfolio in Review

As of Q1 2026, TCG Crossover Management held 54 positions worth $3.5B, up 16% from $3.02B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

TCG Crossover Management deployed $174M of net new capital in Q1 2026, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Disc Medicine: 1,341,862 shares worth $85.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Abivax, an estimated $74.6M trimmed.

  • TCG Crossover Management's largest Q1 2026 buy was Disc Medicine: 1,341,862 shares worth $85.8M.
  • TCG Crossover Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $94.1M increase.
  • TCG Crossover Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $74.6M.
  • TCG Crossover Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $87.5M.
  • TCG Crossover Management's ten largest holdings make up 61% of its $3.5B portfolio in Q1 2026.
  • TCG Crossover Management opened 11 new positions and closed 5 in Q1 2026.
  • TCG Crossover Management's portfolio value rose 16% quarter-over-quarter to $3.5B.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.